American Society of Hematology

Figure 5

$Genetic ablation of CD25 prevents pathogenesis of CML. (A) Survival of Il2ra+/+ (n = 11) or Il2ra−/− (n = 10) LSK-derived CML mice. (B-C) Spleen weight (B) and percentage of BCR-ABL+ cells in the spleen (C) of Il2ra+/+ or Il2ra−/− LSK–derived CML mice were examined 11 days after transplantation (n = 4; means ± SD). (D-E) Flow cytometric analysis of the frequency (D; means ± SD) and number (E; means ± standard error of the mean) of bone marrow LSK cells in Il2ra+/+ or Il2ra−/−LSK–derived CML mice (n = 4). (F) qPCR analysis of IL-4, IL-6, IL-13, and TGF-β2 mRNA in the indicated fractions from Il2ra+/+ or Il2ra−/− LSK–derived CML mice (means ± SD, n = 4). *P < .05; **P < .01. mRNA, messenger RNA.$

Genetic ablation of CD25 prevents pathogenesis of CML. (A) Survival of Il2ra^+/+ (n = 11) or Il2ra^−/− (n = 10) LSK-derived CML mice. (B-C) Spleen weight (B) and percentage of BCR-ABL⁺ cells in the spleen (C) of Il2ra^+/+ or Il2ra^−/− LSK–derived CML mice were examined 11 days after transplantation (n = 4; means ± SD). (D-E) Flow cytometric analysis of the frequency (D; means ± SD) and number (E; means ± standard error of the mean) of bone marrow LSK cells in Il2ra^+/+ or Il2ra^−/−LSK–derived CML mice (n = 4). (F) qPCR analysis of IL-4, IL-6, IL-13, and TGF-β2 mRNA in the indicated fractions from Il2ra^+/+ or Il2ra^−/− LSK–derived CML mice (means ± SD, n = 4). *P < .05; **P < .01. mRNA, messenger RNA.

This Feature Is Available To Subscribers Only